153 results about "Colony formation" patented technology

The present invention relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly, metastatic cancer. In one embodiment, the methods of the invention comprise the administration of an effective amount of one or more antibodies that bind to EphA4 and agonize EphA4. In another embodiment, the methods of the invention comprise the administration of an effective amount of one or more antibodies that bind to EphA4 and inhibit cancer cell colony formation in soft agar or tubular network formation in three-dimensional basement membrane or extracellular matrix preparation. In another embodiment, the methods of the invention comprise the administration of an effective amount of one or more antibodies that preferentially binds to an EphA4 epitope that is exposed on cancer cells but not non-cancer cells. In another embodiment, the methods of the invention comprise the administration of an effective amount of one or more antibodies that bind to EphA4 with a very low Koff to reduce EphA4 expression and, thereby, inhibit tumor cell growth and/or metastasis. The invention also provides pharmaceutical compositions comprising one or more EphA4 antibodies of the invention either alone or in combination with one or more other agents useful for cancer therapy.

This invention provides an agonist antibody to a human thrombopoietin receptor (alias: human c-Mpl). More particularly, this invention provides an agonist antibody to a human thrombopoietin receptor, wherein the agonist antibody comprises: antibody constant regions comprising (1) amino acid sequences in a heavy chain constant region and a light chain constant region of a human antibody, (2) an amino acid sequence of a heavy chain constant region with a domain substituted between human antibody subclasses, and an amino acid sequence of a light chain constant region of a human antibody, or (3) amino acid sequences comprising a deletion(s), substitution(s), addition(s), or insertion(s) of one or several amino acid residues in the amino acid sequences of (1) or (2) above; and antibody variable regions capable of binding to and activating a human thrombopoietin receptor; and wherein the agonist antibody has the properties: (a) that the antibody induces colony formation at a concentration of 10,000 ng/ml or lower as determined by the CFU-MK colony formation assay using human umbilical-cord-blood-derived CD34+ cells; and (b) that the antibody has a maximal activity at least 50% higher than that of PEG-rHuMGDF and an 50% effective concentration (EC50) of 100 nM or less in the cell proliferation assay using UT7/TPO cell. Also provided is a pharmaceutical composition for treating thrombocytopenia comprising said antibody.

The invention discloses a microbial inoculum for degrading straw and the active ingredients of the microbial inoculum comprise Trichoderma viride, Trichoderma aureoviride and forage Paenibacillus pabuli. The colony formation unit ratio of Trichoderma viride to Trichoderma aureoviride and forage Paenibacillus pabuli in the microbial inoculum is (0.8-1.2):(0.8-1.2):(0.8-1.2). The microbial inoculumfor degrading straw of the invention can mature straw fast to prepare organic fertilizer, and the prepared organic fertilizer can be uses as a base fertilizer and can obviously improve the quality ofvegetables.

Pharmaceutical compositions and methods of using them. Lipid formulations of a glutathione analog and methods of manufacturing them. Their use to stimulate hematopoiesis, protect hematopoietic cells from damage caused by radiation or chemotherapy, or potentiate the stimulatory action of one or a combination of cytokines on colony formation by hematopoietic progenitor cells, protect a subject from a destructive effect of a chemotherapeutic agent or irradiation, or to potentiate the effect of a chemotherapeutic agent.

The chemokine receptor CXCR4 is a co-receptor for T-tropic strains of HIV-1. A number of small molecule antagonists of CXCR4 are in development, but all are likely to lead to adverse effects due to the physiological function of CXCR4. To prevent these complications, allosteric agonists may be therapeutically useful as adjuvant therapy in combination with small molecule antagonists. A synthetic cDNA library coding for 160,000 different SDF-based peptides was screened for CXCR4 agonist activity in a yeast strain expressing functional receptor. Peptides that activated CXCR4 in an autocrine manner induced colony formation. Two peptides, designated RSVM and ASLW, were identified as novel agonists that are insensitive to the CXCR4 antagonist AMD3100. In chemotaxis assays using the acute lymphoblastic leukemia cell line CCRF-CEM, RSVM behaves as a partial agonist and ASLW as a superagonist. The superagonist activity of ASLW may be related to its inability to induce receptor internalization. In CCRF-CEM cells, the two peptides are also not inhibited by another CXCR4 antagonist, T140, or the neutralizing monoclonal antibodies 12G5 and 44717.111. These results suggest that alternative agonist binding sites are present on CXCR4 that could be screened to develop molecules for therapeutic use.

A method to remediate water includes preparing a microbial solution with microbes, a growth medium, and water; iteratively and selectively breeding generations of microbes to arrive at a predeterminedmicrobial solution in a highly concentrated form of at least 1*109 cfu/ml (colony-forming units per milliliter); and dispensing the microbial solution into the water, wherein the microbes metabolizesexcess nutrients and uses microbial desalination to reduce water salinity.

The invention discloses a Bu lactobacillus preparation that contains 1*109-1*1011 Bu lactobacillus colony forming unit. It also discloses the manufacture method and the usage. It could used to improve the quality of corn silage.

The flavonoid family of phytochemicals, particularly those derived from soy, has received attention regarding their hormonal activity and their effects on human health and disease. The types and amounts of these compounds in soy and other plants are controlled by both constitutive expression and stress-induced biosynthesis. The health benefits of soy may therefore be dependent upon the amounts of the various hormonally active phytochemicals present. We have identified increased biosynthesis of the isoflavonoid phytoalexin compounds, Glyceollins I, II and III, in soy plants grown under stressed conditions (elicited soy), which exhibit marked anti-estrogenic effects on ER function. Here we demonstrate that specific glyceollins, isolated from elicited soy, displayed anti-estrogenic activity, suppressing basal and estrogen stimulated colony formation of ER-positive estrogen dependent breast cancer cells and inhibiting ER-dependent gene expression of progesterone receptor (PgR) and stromal derived factor-1 (SDF1/CXCL12). Examining the effects of glyceollin on in vivo tumor formation/growth we demonstrate the ability of glyceollins to significantly suppress basal and estrogen-stimulated tumor growth of ER-positive MCF-7 breast and BG-1 ovarian carcinoma cells in ovariectomized female nude mice. We further demonstrate that the effects of glyceollins on suppression of tumor growth correlate with inhibition of estrogen stimulated PgR expression. In contrast to the uterotropic activity of tamoxifen the glyceollins displayed no uterine agonist activity. The Glyceollin (I-III) compounds may represent an important component of the health effects of soy as well as represent novel anti-estrogens useful in the prevention or treatment of breast and ovarian carcinoma.

The invention provides a probiotic composition and a preparation method and application thereof. The probiotic composition comprises raw materials of lactobacillus reuteri, lactobacillus acidophilus and bifidobacterium animalis, wherein the weight ratio of the lactobacillus reuteri to the lactobacillus acidophilus to the bifidobacterium animalis is (1.5-2.5):(0.5-1.5):(0.5-1.5). The colony forming units of the lactobacillus reuteri, the lactobacillus acidophilus or the bifidobacterium animalis in unit weight are the same. The lactobacillus reuteri is preserved in China Center for Type Culture Collection with the preservation number of 209138, and the lactobacillus acidophilus and/or the bifidobacterium animalis preserved in China General Microbiological Culture Collection Center with the preservation number of CGMCC 15210 are/is bifidobacterium animalis BB-115. The probiotic composition can relieve the symptom of slow transit constipation under the condition of low dosage, and can remarkably and effectively regulate gastrointestinal regulatory peptide indexes related to constipation, such as P substance (SP), gastrin (Gas) and vasoactive peptide (VIP).

The invention relates to a cell population comprising minimal volume of orbital fat-derived stem cells (OFSCs) and its isolation, purification, characterization and application. The OFSCs of the invention are capable of multilineage development and express at least CD90 and CD 105 but not hematopoietic and epithelial markers. The OFSCs have colony formation ability and multi-lineage differentiation ability. They possess at least osteogenic, chondrogenic and adipogenic differentiation capacity; besides mesodermal tri-linage differentiation, the OFSCs have corneal epithelial differentiation potential. Taking together, orbital fat tissues are a novel source for multi-potent stem cells which possess multiple therapeutic potential. Therefore, the OFSCs can be used in cell therapy and tissue engineering.

Disclosed is a method and compositions for the differential expansion of fetal cells over maternal cells. In the method, cells from a sample of maternal blood containing CD34+ cells of both maternal and fetal origin are incubated in the presence of Stem Cell Factor in serum free media. It has been discovered that incubation of fetal cells in the presence of SCF will preferentially expand the fetal cells relative to adult cells. Fetal cells can also be identified, enriched or obtained by differential expansion of the fetal cells during colony formation. It has been discovered that differential expansion of fetal cells can result in colonies of fetal cells that are larger than colonies of adult cells. The fetal CD34+ cells can be expanded without generation of significant clonal genetic artifacts during expansion. Also disclosed is a method and compositions for producing differentiated fetal cells. It has been discovered that differentiated fetal cells have markers that distinguish the fetal cells from adult cells. Also disclosed are fetal cells made or obtained using the disclosed methods. For example, disclosed are expanded and/or differentiated fetal cells. The disclosed fetal cells can be used for any purpose and in any way that fetal cells can be used. The disclosed fetal cells are particularly useful for prenatal analysis of a gestating fetus.

An alternative HER-2/neu product, herstatin, consists of subdomains I and II from the ectodomain of p185HER-2 and a unique 79 amino acid C-terminus encoded by intron 8. Recombinant herstatin added to cells was found to bind to and inhibit p185HER-2. The effects of ectopic expression of herstatin in combination with either p185HER-2 or with its homolog, the EGF receptor, in several cell lines was studied. Cotransfection of herstatin with HER-2 inhibited p185HER-2 levels and caused an approximate 8 fold reduction in p185 tyrosine phosphorylation. Inhibition of p185HER-2 tyrosine phosphorylation corresponded to a dramatic decline in colony formation by cells that coexpressed p185HER-2 and herstatin. Herstatin also interfered with EGF activation of the EGF receptor in cotransfected cells demonstrated by impaired receptor tyrosine phosphorylation, reduced receptor down-regulation, and growth suppression. For both p185HER-2 and the EGF receptor, the extent of inhibition was affected by the expression levels of herstatin relative to the receptor. Herstatin is an autoinhibitor of p185HER-2 and expands its inhibitory activity to another member of the group I family of receptor tyrosine kinases, the EGF receptor.

The invention discloses a microbial powder, an infant yoghourt and a preparation method thereof. The microbial powder comprises a compound microbial powder of streptococcus thermophilus STI-13 and streptococcus thermophilus Body-3 at a ratio of 1:1 to 1:4 by colony forming unit quantity. The infant yoghourt obtained by fermentation by using the microbial powder is free of D-lactic acid, and the protein component, the fat structure component and the fatty acid component are all similar to those of breast milk, therefore the infant yoghourt can be favorably digested and assimilated by infants.

The present invention discloses an agonistic antibody directed against human thrombopoietin receptor (also referred to as 'human c-Mpl). Specifically, the antibody has a constant region having a set of amino acid sequences selected from the following items (1) to (3): (1) amino acid sequences for a heavy-chain constant region and a light-chain constant region of a human antibody; (2) an amino acid sequence for a human antibody heavy-chain constant region in which the domain is replaced by one of other human antibody subclass and an amino acid sequence for a human antibody light-chain constant region; and (3) a set of amino acid sequences having the deletion, substitution, addition or insertion of one or several amino acid residues in each of the amino acid sequences shown in (1) and (2), and the antibody has a variable region capable of binding to a human thrombopoietin receptor to activate the receptor. The antibody also has the following properties: (a) the antibody can induce the formation of a colony at a concentration of 10,000 ng/mL or less in the CFU-MK colony formation assay using a human umbilical cord blood CD34+ cell; and (b) the antibody has the maximum activity higher than that of PEG-rHuMGDF by 50% or more and a 50% effective concentration (EC50) of 100 nM or less in the cell growth assay using an UT7/TPO cell. Also disclosed is a pharmaceutical composition for the treatment of thrombocytopenia, which comprises the antibody.

The invention discloses a Chinese medicinal composition for raising leucocytes, which is mainly prepared from the following raw material medicaments in part by weight: 6 to 60 parts of astragalus, 6 to 60 parts of Siberian solomonseal rhizome, 6 to 60 parts of Mongolian snakegourd root and 3 to 30 parts of epimedium herb. The invention also discloses a method for preparing the Chinese medicinal composition and application thereof in preparation of a medicament for treating leucopenia, improving immune function of an organism, promoting proliferation of marrow hematopoietic stem/progenitor cells, protecting hemopoietic microenvironment, repairing the damage and harm to marrow hematopoietic tissues by radioactive rays, preventing and controlling marrow suppression of chemoradiotherapy, promoting colony formation of granulocytes and monocytes, improving Chinese medicinal symptoms and living quality of patients with cancer, or promoting the recovery of patients with Qi-Yin deficiency.

The invention discloses a construction method of a lung cancer radiation resistance cell strain. The method includes the following steps of inoculating lung cancer cells in a six-hole plate when the lung cancer cells are conventionally bred to the logarithmic phase, placing the six-hole plate at the center of an irradiation field, covering the bottom face of the six-hole plate with tissue equivalent filler 1.5 cm thick, perpendicularly transmitting 6MV-X rays according to the dose rate of 300 cGy/min and the source skin distance of 100 cm, sequentially conducting irradiation according to the dose of 2 Gy, 4 Gy, 6 Gy, 8 Gy and 10 Gy each for two times till the total dose reaches 60 Gy, continuing to conduct breeding and passage to five or more generations till the cellular morphology and multiplication are stable, and conducting cryopreservation for standby application. The construction method is small in irradiation time number, short in construction time, small in cell contamination probability and superior to a small-dose equal-segmentation irradiation method; the colony formation experimental result shows that the radiation resistance of the lung cancer radiation resistance cell strain constructed according to the method is higher than that of lung cancer radiation resistance cell strains constructed according to the sublethal dose irradiation method.

The invention discloses a method for separation and purification of Ochrobactrum sp. with deoxidizing Cr 6+, which solves the problem of that prior microorganism is difficult to isolated culture when microorganism disposes alkali waste water with Cr 6+. Picking alkali waste soil sample with Cr 6+ which is inoculated on organic LB medium to process enriched culture generation, adopting selective liquid medium Cr-G which is improved by inventor to process passage culture, and then adopting single-layer flat-plate and improved solid medium to process streak culture. The invention is capable of realizing separation and purification of Ochrobactrum sp. with deoxidizing Cr 6+ in alkality environment, adopting single-layer solid medium and optimize culture condition, wherein culture component is simple and formation rate of bacterial colony is higher.

An NGF-containing pharmaceutical composition used for treating corneal epithelium injuries is disclosed. The composition includes an NGF (preferably a human-derived NGF). The composition (in a form of eye drops preferably) can promote proliferation and clonality capabilities of corneal limbal stem cells, and can effectively promote corneal epithelium injury healing including healing of continuous corneal epithelium injuries, diabetic keratopathy treatment, nervous keratitis treatment and treatment of corneal limbal stem cell deficiency.

The invention discloses a preparation method of a post-resuscitation protective agent for refrigerated umbilical cord blood hematopoietic stem cells, and aims to solve problems that in existing pre-treatment of resuscitating the refrigerated umbilical cord blood hematopoietic stem cells by using normal saline, the cells are easy to be agglomerated, cell debris is increased, a survival rate is reduced and the number of the cells is reduced. The method comprises the following steps: one, preparing buffer solution; two, preparing plasma without fibrin; and three, adding low-molecular-weight heparin sodium, hydroxyethyl starch and polyethylene glycol to the buffer solution; and finally adding the plasma without fibrin, completing. The protective agent is capable of effectively protecting the survival rate of the cells, wherein the cells are not easy to be agglomerated, and cell colony formation is better, effectively protecting activity of the umbilical cord blood hematopoietic stem cellsafter resuscitation, and the number of the cells, wherein the cells are not agglomerated, and guaranteeing a formation force of a colony. The protective agent is applied to the preparation field of the post-resuscitation protective agent for the hematopoietic stem cells.